Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$0.47 -2.6%	$0.43	$0.30 ▼ $3.33	$11.13M	-1.23	3.22 million shs	468,120 shs
CERO CERo Therapeutics	$9.30 -1.6%	$11.74	$6.71 ▼ $895.40	$3.59M	0.48	597,247 shs	29,573 shs
ERNA Ernexa Therapeutics	$2.00 +0.8%	$2.86	$1.75 ▼ $39.38	$14.68M	5.3	369,307 shs	20,994 shs
PRPH ProPhase Labs	$0.42 +3.5%	$0.35	$0.22 ▼ $3.74	$17.36M	-0.41	6.16 million shs	419,846 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	-0.88%	-14.06%	+29.03%	+47.48%	-77.47%
CERO CERo Therapeutics	+2.49%	-15.46%	+5.89%	-32.33%	-98.24%
ERNA Ernexa Therapeutics	+8.79%	+5.32%	-39.73%	-27.07%	-92.58%
PRPH ProPhase Labs	+5.68%	+15.67%	+8.03%	+16.68%	-89.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	2.4875 of 5 stars	3.5	3.0	2.7	1.7	0.0
CERO CERo Therapeutics	3.6709 of 5 stars	3.7	4.0	2.0	0.8	0.0
ERNA Ernexa Therapeutics	0.9477 of 5 stars	0.0	5.0	1.8	1.7	0.0
PRPH ProPhase Labs	0.9104 of 5 stars	0.0	5.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$8.00	1,587.76% Upside
CERO CERo Therapeutics	3.33	Buy	$45.00	383.66% Upside
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
PRPH ProPhase Labs	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CERO, ACXP, ERNA, and PRPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/23/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
5/30/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/30/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/19/2025	CERO CERo Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/15/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$8.00
4/22/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$220.00 ➝ $220.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	($41.98) per share	N/A
ERNA Ernexa Therapeutics	$580K	25.32	N/A	N/A	$0.50 per share	3.99
PRPH ProPhase Labs	$6.77M	2.56	N/A	N/A	$0.25 per share	1.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$0.70	N/A	N/A	N/A	N/A	-526.78%	-223.78%	8/8/2025 (Estimated)
CERO CERo Therapeutics	-$8.30M	N/A	0.00	∞	N/A	N/A	N/A	-199.71%	8/13/2025 (Estimated)
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-285.71%	8/11/2025 (Estimated)
PRPH ProPhase Labs	-$53.36M	-$1.26	N/A	N/A	N/A	N/A	-184.38%	-64.59%	8/13/2025 (Estimated)

Latest CERO, ACXP, ERNA, and PRPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	PRPH ProPhase Labs	-$0.18	-$0.12	+$0.06	$0.12	$2.45 million	$1.43 million
5/15/2025	N/A	CERO CERo Therapeutics	N/A	-$31.80	N/A	-$1.59	N/A	N/A
5/12/2025	Q1 2025	ACXP Acurx Pharmaceuticals	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
PRPH ProPhase Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	1.93	1.93
CERO CERo Therapeutics	N/A	0.73	0.73
ERNA Ernexa Therapeutics	N/A	0.21	0.21
PRPH ProPhase Labs	0.30	1.03	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
CERO CERo Therapeutics	29.64%
ERNA Ernexa Therapeutics	70.55%
PRPH ProPhase Labs	9.45%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	26.00%
CERO CERo Therapeutics	12.72%
ERNA Ernexa Therapeutics	1.50%
PRPH ProPhase Labs	20.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	23.48 million	17.38 million	Optionable
CERO CERo Therapeutics	8	386,000	337,000	N/A
ERNA Ernexa Therapeutics	10	7.36 million	7.26 million	No Data
PRPH ProPhase Labs	130	41.54 million	32.94 million	Optionable

CERO, ACXP, ERNA, and PRPH Headlines

Recent News About These Companies

ProPhase Labs Regains Nasdaq Compliance with New Appointment

July 1 at 9:59 AM | tipranks.com

ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - Morningstar

June 27, 2025 | morningstar.comM

ProPhase Labs Inc. Receives 180-Day Extension from Nasdaq to Regain Bid Price Compliance

June 26, 2025 | quiverquant.comQ

ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

June 26, 2025 | globenewswire.com

Prophase Labs Appoints Carolina Abenante as Director

June 25, 2025 | tipranks.com

ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer

June 17, 2025 | globenewswire.com

ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform

June 6, 2025 | globenewswire.com

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

May 21, 2025 | seekingalpha.com

Earnings call transcript: ProPhase Labs beats Q1 2025 EPS forecast, stock rises

May 21, 2025 | investing.com

ProPhase Labs Inc (PRPH) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges

May 21, 2025 | finance.yahoo.com

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript

May 20, 2025 | seekingalpha.com

ProPhase Labs Q1 2025 Earnings Preview

May 19, 2025 | msn.com

ProPhase Labs's Earnings Outlook

May 19, 2025 | benzinga.com

ProPhase Labs Delays Form 10-Q Filing

May 16, 2025 | tipranks.com

ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

May 13, 2025 | globenewswire.com

Covid Test Lab Weighs Unusual Debt-Collection Plan: Bankruptcy

May 13, 2025 | wsj.com

ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024

April 2, 2025 | seekingalpha.com

ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last year

April 1, 2025 | markets.businessinsider.com

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership
3 Tech Stocks Insiders Are Buying: Speculative Plays for June
By Thomas Hughes | June 4, 2025
View 3 Tech Stocks Insiders Are Buying: Speculative Plays for June

CERO, ACXP, ERNA, and PRPH Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$0.47 -0.01 (-2.61%)

As of 12:42 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

CERo Therapeutics NASDAQ:CERO

$9.30 -0.16 (-1.65%)

As of 12:43 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Ernexa Therapeutics NASDAQ:ERNA

$2.00 +0.02 (+0.76%)

As of 12:42 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

ProPhase Labs NASDAQ:PRPH

$0.42 +0.01 (+3.54%)

As of 12:43 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time